Degron Eyes Deals For Novel Molecular Glue Degrader Assets

$1bn+ Takeda Alliance Last Year

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Molecular glue degraders, an emerging drug class expected to unlock the therapeutic potential of historically hard-to-drug targets, have made progress by leaps and bounds over the past few years. (Shutterstock)

More from R&D

More from Interviews